Company profile · Biotech & medical
HanchorBio
英屬開曼群島商漢康生技(股)公司 · 7827
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Hanchor-KY is a biotechnology firm focused on developing novel therapeutics in the field of tumor immunity and new drugs for cancer and autoimmune diseases.[1]
The company uses its proprietary Fc-Based Biopharmaceutical Design (FBDB™) platform to develop biopharmaceuticals with multiple targeting modalities while simultaneously activating both innate and adaptive immune systems to kill tumor cells.[1]
As of 2025, the company has advanced over eight research pipelines using the FBDB™ platform, covering immune checkpoints, tumor microenvironment regulation, and tumor-specific antigens.[2]
The company operates in Taipei, Shanghai, and San Francisco, and its research center is located in Taipei.[2]
Next week's investor conferences, ex-dividend dates and shareholder meetings, only in the email. Every listed Taiwan company reports its November sales by 10 Dec. The free Friday email on 11 Dec has the summary: which supply-chain groups grew and which shrank.
After subscribing, check your inbox (and spam folder) and confirm your subscription. We do this to protect you from spammers.
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$0m | – | – |
2025-05 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-15 to 2026-11-13 | +NT$71m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | HanchorBio Inc. |
|---|---|
| Chinese name | 英屬開曼群島商漢康生技(股)公司 |
| Stock code | 7827 (TWSE) |
| Industry | Biotech & medical |
| Founded | 11 Nov 2020 |
| Listed | 29 May 2026 |
| Paid-in capital | NT$1.4bn |
| Chairman | 劉世高 |
| President | 劉世高 |
| Headquarters | 5F,1 Tiding Blvd. Sec. 1, Neihu Dist. Taipei City, Taiwan |
| Website | https://www.hanchorbio.com |
| Official business description | 免疫治療抗癌生物新藥 |
Facts from MOPS company basic information, retrieved 12 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- Annual report 2025 (English), business scope · annual_report · retrieved 12 Nov 2026
- 關於漢康 - 漢康生技 · website · retrieved 12 Nov 2026
Using it at work? Join the team-plan waiting list
After subscribing, check your inbox (and spam folder) and confirm your subscription. We do this to protect you from spammers.